TRIlogy-4
Multiple myeloma
A Phase 3, randomized study comparing ramantamig (JNJ-79635322) and teclistamab in patients with relapsed or refractory MM who have received ≥3 prior lines of therapy
Phase
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab) or teclistamab (BCMA × CD3 bispecific Ab)
NCT identifier
NCT07258511
Enrollment
N=~400
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- Relapsed or refractory MM patients
- With ≥3 prior lines of therapy (including PI, IMiD, anti-CD38 mAb)
Study
design
Primary outcomes:
- ORR
- PFS
Secondary outcomes†:
- ≥VGPR
- ≥CR
- DOR
- MRD-negative CR
- OS
- TTNT
- Safety
- HRQoL
*Not a complete list of inclusion and exclusion criteria. †Not a complete list of outcomes.
Ab, antibody; BCMA, B-cell maturation antigen; BsAb, bispecific antibody; CD, cluster of differentiation; CR, complete response; DOR, duration of response; GPRC5D, G protein–coupled receptor class C group 5 member D; HRQoL, health-related quality of life; IMiD, immunomodulatory agent; mAb, monoclonal antibody; MRD, minimal residual disease; MM, multiple myeloma; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PI, proteasome inhibitor; R, randomized; TTNT, time to next line of therapy; VGPR, very good partial response.